Latest Innovation News

Vitrafy Life Sciences has entered a 12-month exclusive partnership with IMV Technologies to integrate cryopreservation technologies, securing up to A$930k in fees and milestone payments.

Aquirian Limited reports a robust first half of FY26 with revenue up 27.4% and EBITDA more than doubling, driven by strategic facility upgrades and promising joint ventures.

Osteopore Limited has completed the full subscription of Tranche 1 under its A$20 million convertible notes facility, raising an additional A$250,000 to support ongoing business and future projects.

MetalsTech Limited is progressing its Pre-Feasibility Study for the Sturec Gold Mine in Slovakia, targeting completion in the first half of 2026, alongside key board appointments aimed at driving the project forward.

Tasman Resources has clarified the reasons behind its recent share price jump, pointing to a significant new investor, upcoming drilling programs, and a rising stake in Eden Innovations. The company reassures the market it remains fully compliant with ASX disclosure rules.

Recce Pharmaceuticals has received a $5.3 million R&D tax rebate from the Australian Taxation Office, providing a significant cash injection to support its innovative synthetic anti-infective drug development programs.

Neuren Pharmaceuticals’ partner Acadia projects DAYBUE sales to reach around US$700 million by 2028, driven by US market expansion and international approvals. The launch of a new formulation and ongoing clinical trials in Japan underpin this optimistic outlook.

HighCom Limited appoints seasoned executive Geoffrey Knox as Executive Chairman and CEO, signaling a strategic push to strengthen its defence manufacturing and sustainment operations in Australia and the US.

Great Dirt Resources has confirmed high-grade manganese mineralisation in NSW and identified 24 new exploration targets through advanced R&D techniques, supported by a $315k tax rebate and a strong cash position.

Racura Oncology has launched a strategic collaboration with Emory University to investigate (E,E)-bisantrene’s potential to overcome resistance to osimertinib in EGFR-mutated non-small cell lung cancer. This partnership aims to bolster Racura’s HARNESS-1 clinical trial and strengthen its position in the competitive lung cancer treatment landscape.

Ion Video Limited has completed significant restructuring, strengthened its Melbourne-based tech team, and raised $2.95 million, positioning itself for a technology relaunch in February 2026 with a cash runway extending to mid-2027.

Proteomics International Laboratories has appointed David Morris as CEO and Managing Director, marking a strategic shift towards commercialising its Promarker® diagnostic technology. Morris brings extensive global healthcare leadership experience to lead the company’s next growth phase.